GeneDx Holdings Corp. Reports Board Changes and Compensation Updates
Ticker: WGSWW · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1818331
| Field | Detail |
|---|---|
| Company | Genedx Holdings Corp. (WGSWW) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $379.50, $450,000, $75,000, $2,700,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
TL;DR
GeneDx reshuffled its board and updated exec pay on Jan 2nd. Expect strategic shifts.
AI Summary
GeneDx Holdings Corp. announced on January 2, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory plans for key personnel. This report also includes financial statements and exhibits relevant to these corporate governance and compensation matters.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance, impacting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and financial performance.
Key Players & Entities
- GeneDx Holdings Corp. (company) — Registrant
- Sema4 Holdings Corp. (company) — Former Company Name
- CM Life Sciences, Inc. (company) — Former Company Name
- January 2, 2025 (date) — Date of Report
FAQ
What specific roles have been affected by the departure of certain officers?
The filing indicates the departure of certain officers but does not specify the exact roles in this summary.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in this summary.
What are the key details of the updated compensatory arrangements?
The filing notes updates to compensatory arrangements for certain officers, but specific details are not provided in this summary.
When did GeneDx Holdings Corp. change its name from Sema4 Holdings Corp.?
GeneDx Holdings Corp. changed its name from Sema4 Holdings Corp. on July 21, 2021.
What is the primary business of GeneDx Holdings Corp. according to its SIC code?
GeneDx Holdings Corp. is classified under SERVICES-HEALTH SERVICES [8000].
Filing Stats: 1,199 words · 5 min read · ~4 pages · Grade level 11 · Accepted 2025-01-02 17:14:11
Key Financial Figures
- $0.0001 — stered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market L
- $379.50 — mon stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market
- $450,000 — g for (i) a total annual base salary of $450,000, (ii) a target annual bonus of 50% of D
- $75,000 — lary, (iii) a one-time sign-on bonus of $75,000 payable in a single lump-sum within 30
- $2,700,000 — s with an aggregate grant-date value of $2,700,000, which will vest in equal annual instal
Filing Documents
- wgs-20250102.htm (8-K) — 32KB
- cooemploymentagreement.htm (EX-10.1) — 90KB
- pressrelease-appointmentof.htm (EX-99.1) — 7KB
- bluelogo600x208a.jpg (GRAPHIC) — 16KB
- wgs-20250102_g1.jpg (GRAPHIC) — 16KB
- 0001818331-25-000002.txt ( ) — 391KB
- wgs-20250102.xsd (EX-101.SCH) — 2KB
- wgs-20250102_def.xml (EX-101.DEF) — 17KB
- wgs-20250102_lab.xml (EX-101.LAB) — 29KB
- wgs-20250102_pre.xml (EX-101.PRE) — 17KB
- wgs-20250102_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On January 2, 2025, the Company issued a press release announcing Dr. Dechairo's appointment as Chief Operating Officer, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No Description 10.1 Employment Agreement by and between Dr. Bryan Dechairo and GeneDx, LLC, dated as of October 10, 2024. 99.1 Press Release, dated January 2, 2025, regarding the registrant's appointment of its new Chief Operating Officer.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEDX HOLDINGS CORP. Date: January 2, 2025 By: /s/ Katherine Stueland Name: Katherine Stueland Title: Chief Executive Officer